Browsing by Author Cheng, AL

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 中
Showing results 10 to 22 of 22 < previous 
TitleAuthor(s)Issue Date
 
Efficacy and safety of every-2-weeks cetuximab combined with FOLFOX or FOLFIRI as first-line therapy in patients with KRAS wild-type metastatic colorectal cancer (mCRC): an Asia-Pacific nonrandomized phase II study (APEC)
Proceeding/Conference:Journal of Clinical Oncology
Cheng, ALCornelio, GHShen, LPrice, TJYang, TSChung, IJDai, GLin, JKSharma, AYeh, KHMa, BZaatar, AGuan, ZZMasood, NSrimuninnimit, VYau, TCCSarholz, BLim, RSC
2013
 
Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 APEC Study
Journal:Clinical Colorectal Cancer
Cheng, ALCornelio, GShen, LPrice, TYang, TSChung, IJDai, GHLin, JKSharma, AYeh, KHMa, BZaatar, AGuan, ZMasood, NSrimuninnimit, VYau, TCCGibbs, PWang, XDoval, DCSeung-Taek, OShim, BYGorospe, CWang, HMSirachainan, EHill, ASuh, KWBeier, FChatterjee, SLim, R
2017
 
Health-Related Quality-of-Life Impact of Pembrolizumab Versus Best Supportive Care in Previously Systemically Treated Patients With Advanced Hepatocellular Carcinoma: KEYNOTE-240
Journal:Cancer
Ryoo, BYMerle, PKulkarni, ASCheng, ALBouattour, MLim, HYBreder, VEdeline, JChao, YOgasawara, SYau, TGarrido, MChan, SLDaniele, BNorquist, JMChen, ESiegel, ABZhu, AXFinn, RSKudo, M
2021
 
Liver cancer working group report
Journal:Japanese Journal of Clinical Oncology
Kudo, MHan, KHKokudo, NCheng, ALChoi, BIFuruse, JIzumi, NPark, JWPoon, RTSakamoto, M
2010
 
Management of colon cancer: resource-stratified guidelines from the Asian Oncology Summit 2012
Journal:Lancet Oncology
Ku, GTan, IBYau, TCCBoku, NLaohavinij, SCheng, ALKang, YKde Lima Lopes, G
2012
 
Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: A Subgroup Analysis of Asian Patients in the Phase 3 KEYNOTE-240 Trial
Journal:Liver Cancer
Kudo, MLim, HYCheng, ALChao, YYau, TCCOgasawara, SKurosaki, MMorimoto, NOhkawa, KYamashita, TLee, KHChen, ESiegel, ABRyoo, BY
2020
 
Pharmacodynamic biomarkers predictive of survival benefit with lenvatinib in unresectable hepatocellular carcinoma: from the phase III REFLECT study
Journal:Clinical Cancer Research
Finn, RSKudo, MCheng, ALWyrwicz, LNgan, RKCBlanc, JFBaron, ADVogel, AIkeda, MPiscaglia, FHan, KHQin, SMinoshima, YKanekiyo, MRen, MDairiki, RTamai, TDutcus, CEIkezawa, HFunahashi, YEvans, TRJ
2021
 
Randomized, open-label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinoma
Journal:Hepatology
Cheng, ALThongprasert, SLim, HYSukeepaisarnjaroen, WYang, TSWu, CCChao, YChan, SLKudo, MIkeda, MKang, YKPan, HNumata, KHan, GBalsara, BZhang, YRodriguez, AMZhang, YWang, YPoon, RTP
2016
 
Recent advances in the prevention of hepatocellular carcinoma recurrence
Journal:Seminars in Liver Disease
Lu, LCCheng, ALPoon, RTP
2014
 
Safety, efficacy, and pharmacodynamics of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma: Randomized expansion of a phase I/II study
Journal:Journal of Clinical Oncology
Kelley, RKSangro, BHarris, WIkeda, MOkusaka, TKang, YKQin, STai, DWMLim, HYYau, TYong, WPCheng, ALGasbarrini, ADamian, SBruix, JBorad, MBendell, JKim, TYStandifer, NHe, PMakowsky, MNegro, AKudo, MAbou-Alfa, GK
2021
 
Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial
Journal:ESMO Open
Kelley, RKRyoo, BYMerle, PPark, JWBolondi, LChan, SLLim, HYBaron, ADParnis, FKnox, JCattan, SYau, TLougheed, JCMilwee, SEl-Khoueiry, ABCheng, ALMeyer, TAbou-Alfa, GK
2020
 
Serum alpha-fetoprotein levels and clinical outcome in the phase 3 CELESTIAL study of cabozantinib versus placebo in patients with advanced hepatocellular carcinoma
Journal:Clinical Cancer Research
Kelley, RKMeyer, TRimassa, LMerle, PPark, JWYau, TChan, SLBlanc, JFTam, VCTran, ADadduzio, VMarkby, DWKaldate, RCheng, ALEl-Khoueiry, ABAbou-Alfa, GK
2020
 
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma
Journal:Journal for ImmunoTherapy of Cancer
Greten, TFAbou-Alfa, GKCheng, ALDuffy, AGEl-Khoueiry, ABFinn, RSGalle, PRGoyal, LHe, ARKaseb, AOKelley, RKLencioni, RLujambio, AMabry Hrones, DPinato, DJSangro, BTroisi, RIWilson Woods, AYau, TZhu, AXMelero, I
2021
Showing results 10 to 22 of 22 < previous